Market Overview

Vertex, JNJ's Janssen Enter Agreement for Phase 2 Hepatitis C Study

Related VRTX
Biogen And Gilead Sciences Catch The Eye Of Short Sellers
4 Biotechs Piper Jaffray Is Buying On The Pullback
Premarket Biotech Digest: CLL Treatment, Gilead CEO Sells, Acelity IPO (Seeking Alpha)

Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it
has entered into a non-exclusive collaboration with Johnson & Johnson's (NYSE: JNJ) Janssen
Pharmaceuticals, Inc. to conduct a Phase 2 proof-of-concept study of an
all-oral regimen for the treatment of hepatitis C containing Vertex's
nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135
and Janssen's protease inhibitor simeprevir (TMC435). As part of the
collaboration, Janssen will conduct a drug-drug interaction study with
VX-135 and simeprevir to support the planned initiation of a Phase 2
proof-of-concept study in early 2013, pending discussions with
regulatory authorities. The Phase 2 study is expected to evaluate
safety, tolerability and viral cure rates using a 12-week combination of
VX-135 and simeprevir. The companies will jointly fund development

See full press release

Posted-In: News Guidance Contracts Management Stock Split Global


Related Articles (VRTX + JNJ)

Get Benzinga's Newsletters